Nirapirib (ZEJULA)





- Initially developed by Merck then licensed out to Tesro in June 2012
- Niraparib was FDA approved in March 2017 for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Poly(ADP-ribose) polymerase (PARP)inhibitor
- Highly-selective, potent inhibitor of PARP-1 and -2, with antitumor activity in cells with mutations in the *BRCA1*/2 genes
- Effective for patients with defective homologous recombination







Stewat, E.L. *J. Med. Chem.* 2008, 51, 12, 3349.https://doi.org/10.1021/jm800279t

Barnes, P.J. *Pharmaceuticals* **2010**, *3*, 514; https://doi.org/10.3390/ph3030514

Nirapirib (ZEJULA)

Merck Process Route



Jadav, K. J.; Kambhampati, S.; Chitturi, T. R.; Thennati, R. World Patent WO 2004/001369

Wu, M. Z. China Patent CN 101838301 A, 2010.